• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

    55.54 -0.63 (-1.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,603,893
    Open 56.17
    Bid (Size) 52.00 (100)
    Ask (Size) 56.35 (1,000)
    Prev. Close 56.17
    Today's Range 55.25 - 56.59
    52wk Range 49.26 - 66.28
    Shares Outstanding 183,352,255
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    2 Profitable Stocks Worth Your Attention and 1 We Find Risky
    Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
    Via StockStory
    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals ↗
    Via Chartmill

    Performance

    YTD
    -6.6%
    -6.6%
    1 Month
    +5.6%
    +5.6%
    3 Month
    -7.9%
    -7.9%
    6 Month
    +3.4%
    +3.4%
    1 Year
    -3.4%
    -3.4%

    More News

    Read More
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
    Via StockStory
    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth ↗
    Via Chartmill
    BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance ↗
    Via Chartmill
    Topics Earnings
    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock ↗
    Via Chartmill
    News headline image
    1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
    Via StockStory
    News headline image
    2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down
    Via StockStory
    Topics Credit Cards
    News headline image
    BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook
    Via StockStory
    News headline image
    BioMarin (BMRN) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates
    Via StockStory
    News headline image
    BioMarin (BMRN) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
    Via MarketMinute
    Topics Economy
    News headline image
    2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
    Via StockStory
    News headline image
    Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
    Via StockStory
    Topics Government Stocks World Trade
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
    Via StockStory
    News headline image
    Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
    Via The Motley Fool
    News headline image
    Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
    Via The Motley Fool
    News headline image
    This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
    Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
    What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
    BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
    The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
    What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
    The current price of BioMarin Pharmaceutical Inc. - Common Stock is 55.54
    When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
    The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 06/11/26 04:00 PM ET
    What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
    The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.18B
    How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
    BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.